Oramed Pharmaceuticals Inc. is a technology pioneer in the oral delivery solutions field for drugs currently delivered via injection. Oramed’s Protein Oral Delivery (POD) technology is based on over three decades of research by top scientists at Jerusalem’s Hadassah Medical Center. The company aims to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule. For more information, visit the company website at www.oramed.com.
Oramed Pharmaceuticals Inc. (ORMP) Starts Presentation at LD Micro Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option